The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone (KPd) in patients (Pts) with relapsed/refractory multiple myeloma (RRMM): A Multiple Myeloma Research Consortium multicenter study.
 
Cara Ann Rosenbaum
Honoraria - Celgene
 
Leonor Ano Stephens
No Relationships to Disclose
 
Vishal Kukreti
Honoraria - Amgen; Celgene; Janssen-Ortho; Lundbeck
 
Jeffrey A. Zonder
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Celgene; Prothena
Research Funding - Celgene
 
Craig Cole
No Relationships to Disclose
 
Todd M. Zimmerman
No Relationships to Disclose
 
Donna Ellen Reece
No Relationships to Disclose
 
Jesus G. Berdeja
Research Funding - Abbvie (Inst); Acetylon Pharmaceuticals (Inst); Amgen (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Curis (Inst); Janssen (Inst); Novartis (Inst); Takeda (Inst)
 
Erica Severson
No Relationships to Disclose
 
Andrea Revethis
No Relationships to Disclose
 
Brittany Wolfe
No Relationships to Disclose
 
Kathryn McDonnell
No Relationships to Disclose
 
Jennifer Nam
No Relationships to Disclose
 
Kent A. Griffith
No Relationships to Disclose
 
Andrzej J. Jakubowiak
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Karyopharm Therapeutics; Millennium; Sanofi; Skyline Diagnostics
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Janssen-Ortho; Karyopharm Therapeutics; Millennium; Sanofi; Skyline Diagnostics
Other Relationship - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Karyopharm Therapeutics; Millennium; Sanofi; Skyline Diagnostics